Basilea ceftobiprole enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Basilea initiates a Phase III program for its antibiotic ceftobiprole (BAL5788) for use in complicated skin and skin structure infections, the firm announces Nov. 4. The Swiss company, a spin-off of Roche, describes the agent as "the first of a new generation of anti-[methicillin-resistant Staphylococcus aureus] cephalosporins" that will "combine the well-established advantages of the cephalosporin antibiotic class with an enhanced gram-positive antibacterial spectrum." Ceftobiprole was designed to bind to mutated targets in MRSA. A 700-patient skin/skin structure infections study versus vancomycin is ongoing, with additional studies planned in other severe infection indications. Ceftobiprole has fast-track status for CSSIs due to MRSA and for hospital-acquired pneumonia due to MRSA...
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.